Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 80 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonatal Seizure Clear all

Conditions: Developmental and Epileptic Encephalopathy
Interventions: LP352, Placebo; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 31
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Seizures, Encephalopathy
Interventions: EEG monitoring and treatment of EEG seizures; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Hour to 72 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Autosomal Dominant Hypocalcemia
Interventions: Not listed
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: Up to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more

Conditions: Brain Malformation, Neuronal Migration Disorder, Cognition Disorder, Epilepsy
Interventions: Not listed
Lead sponsor: Harvard University Faculty of Medicine; Other
Eligibility: Not listed
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages, Epilepsy, Cerebral Palsy, Intellectual Disability
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years to 8 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more

Conditions: Perinatal Death, Respiratory Distress Syndrome, Newborn, Hypoxic-Ischemic Encephalopathy, Neonatal Seizure, Meconium Aspiration Syndrome, Intracranial Hemorrhages, Neonatal Hypotension
Interventions: Room air; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Seizures, Disorder of Fetus or Newborn
Interventions: Low dose levetiracetam, High dose levetiracetam; Drug
Lead sponsor: Richard H. Haas; Other
Eligibility: 1 Minute to 14 Days
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions: Anastrozole 1mg, Placebo Oral Tablet; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Electroencephalographic Neonatal Seizures, Epilepsy
Interventions: Lacosamide intravenous, Lacosamide oral, Active Comparator; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: Up to 28 Days
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 11 more

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: Sarah Katie Ihnen; Other
Eligibility: 1 Year to 30 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions: Driving Decision Aid, Older Drivers Website; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month to 23 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Epilepsy, Epilepsy, Generalized, Seizures
Interventions: Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo; Drug
Lead sponsor: Lundbeck LLC; Industry
Eligibility: 2 Years to 60 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 34
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Epilepsy, Seizures, Lennox-Gastaut Syndrome
Interventions: Ketogenic diet; Behavioral
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 1 Year to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cortical Dysplasia
Interventions: Classical ketogenic diet; Dietary Supplement
Lead sponsor: University College, London; Other
Eligibility: 3 Years to 15 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Seizures
Interventions: Bumetanide, Normal Saline as Placebo; Drug
Lead sponsor: Soul, Janet , M.D.; Individual
Eligibility: Up to 44 Weeks
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Urea Cycle Disorders, Organic Acidemias
Interventions: Therapeutic Hypothermia, Standard of Care Therapy; Other
Lead sponsor: Uta Lichter-Konecki; Other
Eligibility: 1 Day to 30 Days
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Milwaukee, Wisconsin

Conditions: Birth Defects, Pregnancy Complications, Epilepsy, Seizures
Interventions: Not listed
Lead sponsor: UCB Pharma; Industry
Eligibility: Female only
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Epilepsy, Seizures, Syncope, Channelopathy, Cardiomyopathies
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
Interventions: ZX008 (Fenfluramine Hydrochloride); Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Lafora Disease
Interventions: Not listed
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Dallas, Texas

Conditions: Generalized Epilepsy, Infantile Spasms, Metabolic Disease, Partial Epilepsy, Seizures
Interventions: 18 FDG; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

ADH1 and ADH2 Disease Monitoring Study (DMS)

Human Epilepsy Genetics--Neuronal Migration Disorders Study

Neonatal Seizure Registry - Developmental Functional EValuation

Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

ESIS in Pediatric DRE

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Advancing Understanding of Transportation Options

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Clobazam in Patients With Lennox-Gastaut Syndrome

Ketogenic Diet for Child Epilepsy and Seizure Control

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

Pilot Study of Bumetanide for Newborn Seizures

Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

Genetic Markers of Cardiovascular Disease in Epilepsy

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Natural History and Functional Status Study of Patients With Lafora Disease

Metabolic Abnormalities in Children With Epilepsy